CONTRAVE
Total Payments
$7.9M
Transactions
75,326
Doctors
24,876
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.8M | 6,314 | 3,029 |
| 2023 | $148,734 | 6,342 | 3,302 |
| 2022 | $175,976 | 10,670 | 5,753 |
| 2021 | $276,609 | 12,720 | 6,316 |
| 2020 | $86,628 | 4,998 | 2,765 |
| 2019 | $122,163 | 4,845 | 2,957 |
| 2018 | $130,916 | 6,498 | 3,966 |
| 2017 | $1.1M | 22,939 | 10,959 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.6M | 1,108 | 71.5% |
| Food and Beverage | $1.1M | 73,013 | 13.8% |
| Honoraria | $758,584 | 389 | 9.6% |
| Consulting Fee | $198,756 | 62 | 2.5% |
| Travel and Lodging | $134,839 | 305 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $54,863 | 5 | 0.7% |
| Education | $13,786 | 437 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $2,700 | 4 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83.91 | 3 | 0.0% |
Payments by Type
Research
$5.6M
1,108 transactions
General
$2.2M
74,218 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NB (Contrave) Cardiovascular Outcomes Trial | Currax Pharmaceuticals LLC | $5.6M | 5 |
Ad
Manufacturing Companies
- Currax Pharmaceuticals LLC $6.5M
- Orexigen Therapeutics, Inc. $1.2M
- Bausch Health US, LLC $86,532
- Nalpropion Pharmaceuticals LLC $53,658
- Nalpropion Pharmaceuticals, Inc. $31,626
Product Information
- Type Drug
- Total Payments $7.9M
- Total Doctors 24,876
- Transactions 75,326
About CONTRAVE
CONTRAVE is a drug associated with $7.9M in payments to 24,876 healthcare providers, recorded across 75,326 transactions in the CMS Open Payments database. The primary manufacturer is Currax Pharmaceuticals LLC.
Payment data is available from 2017 to 2024. In 2024, $5.8M was paid across 6,314 transactions to 3,029 doctors.
The most common payment nature for CONTRAVE is "Unspecified" ($5.6M, 71.5% of total).
CONTRAVE is associated with 1 research study, including "NB (Contrave) Cardiovascular Outcomes Trial" ($5.6M).